News Denmark's Genmab prepares for $500m US IPO Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.
News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News J&J rumoured to be sizing up $12bn Genmab acquisition Speculation mounts that J&J will bid for R&D partner
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News Patient organisations 'too influenced by corporate funders' Researchers have called for action to safeguard the independence of patient advocacy organisations as they increasingly rely on pharma funding.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
